Compare Abeona Therapeutics Inc (ABEO) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs HubSpot Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while HubSpot Inc trades at $209.94 (market cap $11.00B). The key difference: HubSpot Inc is far larger — about 26.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | HUBS | |
|---|---|---|
Market Cap | $421.19M | $11.00B |
Sector | Health | Technology |
52-Week High | $7.45 | $522.97 |
52-Week Low | $4.17 | $170.39 |
Enterprise Value | $276.10M | $9.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
HubSpot (HUBS) trades at $210.12, down 2.68% amid a bearish technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates with $3.26 versus $3.02 expected, but lowered its 2026 customer-growth forecast, causing investor concern. Revenue growth remains robust at 20% year-over-year, while profitability metrics show improvement, with net income margin rising to 4.26% in 2025 from negative figures in prior years.
The outlook is mixed: analyst consensus is bullish with a $233.93 price target, but near-term risks include execution challenges in AI adoption and a securities fraud investigation. Long-term growth depends on successful AI product integration and customer acquisition recovery, though competitive and regulatory pressures persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
